NovoCure Company Profile (NASDAQ:NVCR)

Analyst Ratings

Consensus Ratings for NovoCure (NASDAQ:NVCR) (?)
Ratings Breakdown: 1 Sell Rating(s), 1 Hold Rating(s), 4 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $28.67 (254.35% upside)

Analysts' Ratings History for NovoCure (NASDAQ:NVCR)
Show:
DateFirmActionRatingPrice TargetActions
7/6/2016WedbushReiterated RatingOutperform$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016JPMorgan Chase & Co.Reiterated RatingOverweight$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/24/2016Barclays PLCLower Price TargetSell$16.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/1/2015Deutsche Bank AGInitiated CoverageHold -> Hold$28.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/12/2015Evercore ISIInitiated CoverageBuy$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/27/2015JMP SecuritiesInitiated CoverageOutperform$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for NovoCure (NASDAQ:NVCR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016        
7/28/2016Q216($0.37)($0.48)$15.90 million$17.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2016Q116($0.33)($0.42)$23.65 million$13.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NovoCure (NASDAQ:NVCR)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.32)($0.31)($0.32)
Q2 20161($0.43)($0.43)($0.43)
Q3 20161($0.43)($0.43)($0.43)
Q4 20161($0.42)($0.42)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NovoCure (NASDAQ:NVCR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for NovoCure (NASDAQ:NVCR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/8/2016Michael J AmbrogiCOOSell20,000$12.24$244,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Asaf DanzigerCEOBuy10,000$15.00$150,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2016Robert J Mylod JrDirectorBuy20,000$15.78$315,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for NovoCure (NASDAQ:NVCR)
DateHeadline
07/28/16 05:48 PMU.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.09%
07/28/16 05:48 PMNasdaq Composite Index Closes at 2016 High
07/28/16 05:48 PMWhy Novocure Ltd Is Plunging Today
07/28/16 08:46 AMNovoCure reports 2Q loss
07/26/16 08:47 AMNovocure : NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma
07/26/16 06:18 AMNCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma - [at noodls] - Released : 07/26/2016 Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure ...
07/20/16 08:28 AMEquity Roundup: Stock Performance Focus on Novocure Ltd (NASDAQ:NVCR) - Press Telegraph
07/19/16 03:01 PMNOVOCURE LTD Files SEC form 8-K, Termination of a Material Definitive Agreement -
07/19/16 07:52 AMEarnings Focus and Crowd Sourced Sentiment Review for Novocure Ltd (NASDAQ:NVCR) - TGP
07/18/16 10:55 AMNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 0.82% - Press Telegraph
07/18/16 07:22 AMNovocure Ltd. breached its 50 day moving average in a Bearish Manner : NVCR-US : July 18, 2016 -
07/15/16 10:24 AMNovocure Ltd (NASDAQ:NVCR) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 05:49 PMEnergy stocks up after broker recommendations
07/14/16 05:49 PMNovoCure Ltd. (NVCR) Is Rising Following FDA Approval
07/14/16 09:07 AMNVCR Up On FDA Nod, PeriCoach Now Available OTC, FDA Panel Backs GP2015 - Nasdaq
07/14/16 09:07 AMAnalyst Target and Average Rating Watch: Novocure Ltd (NASDAQ:NVCR) - Press Telegraph
07/13/16 03:28 PMNovocure Receives FDA Approval for Second Generation Optune System - [at noodls] - Released : 07/13/2016 Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients ...
07/13/16 03:01 PM4:01 pm NovoCure receives FDA approval for the premarket approval supplement application for its second generation Optune system -
07/12/16 09:52 AMNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased 0.82% After Market Selling - Press Telegraph
07/12/16 09:52 AMNovocure Ltd (NASDAQ:NVCR) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/11/16 10:11 AMCould Novocure Ltd Decrease Even More? The Stock Formed Multiple Bottom Chart Pattern - Press Telegraph
07/08/16 05:39 PMCan Novocure Ltd (NASDAQ:NVCR) Improve on the Earnings Front? - Engelwood Daily
07/08/16 05:39 PMHow Analysts Feel About Novocure Ltd (NASDAQ:NVCR)? - Press Telegraph
07/07/16 08:29 AMNovocure Limited Ord (NASDAQ:NVCR) Sellers Increased By 0.82% Their Shorts - Engelwood Daily
07/07/16 08:29 AMCompany Stock Focus for Novocure Ltd (NASDAQ:NVCR): Which Way Will Shares Head? - Press Telegraph
07/05/16 11:20 AMNovocure Ltd. – Value Analysis (NASDAQ:NVCR) : July 5, 2016 -
07/04/16 07:19 AMNovocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : July 4, 2016 -
07/01/16 05:34 PMInterview with the Executive Chairman: Novocure Ltd. (NASDAQ:NVCR) - The Wall Street Transcript
06/30/16 03:59 PMNOVOCURE LTD Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
06/30/16 03:00 PMNovocure Announces $75 Million Drawdown under Its Term Loan Agreement through Pharmakon Advisors - [Business Wire] - Novocure announced today that it has provided notice to draw the remaining $75 million under its existing term loan agreement with an investment fund managed by Pharmakon Advisors LP and anticipates receiving funds on July 22, 2016.
06/30/16 08:26 AMNovocure : to Report Second Quarter 2016 Financial Results
06/30/16 06:21 AMNovocure to Report Second Quarter 2016 Financial Results - [at noodls] - Released : 06/30/2016 ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2016 on Thursday, July 28, 2016 at 6:30 ...
06/29/16 05:27 PMNovocure Ltd Can't Be More Safe. Trades Significantly Higher - Press Telegraph
06/29/16 05:27 PMNovocure Ltd on Focus After Forming Multiple Bottom Chart Pattern - Engelwood Daily
06/29/16 05:27 PMEquity Research and Technical Review on Novocure Ltd (NASDAQ:NVCR) - Press Telegraph
06/23/16 06:04 PMNovocure Ltd (NASDAQ:NVCR) Earnings Glance and Target Price Review - Engelwood Daily
06/19/16 09:29 AMCramer: Media sending you off the scent for this stock - Yahoo7 News
06/17/16 07:00 AMStrength Seen in NovoCure (NVCR): Stock Rises by 5.1% -
06/10/16 05:50 PMNovocure Ltd (NASDAQ:NVCR) announced that the (FDA) has approved its investigational device exemption (IDE ... - Inside Trade
06/10/16 07:07 AMNovocure Ltd. breached its 50 day moving average in a Bullish Manner : NVCR-US : June 10, 2016 -
06/08/16 06:18 AMNovocure to Present at JMP Securities 2016 Life Sciences Conference - [at noodls] - Released : 06/08/2016 ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced that Mike Ambrogi, Novocure's Chief Operating Officer, will present at the JMP Securities 2016 Life Sciences ...
06/01/16 06:00 PMNovocure Ltd (NASDAQ:NVCR) Stock Update & Estimates - Stock Tick Tock - Novocure Ltd (NASDAQ:NVCR) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Novocure Ltd (NASDAQ:NVCR) to post earnings of $-0.35 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/01/16 08:29 AMTarget Price and Stock Performance Rundown for Novocure Ltd (NASDAQ:NVCR) - HNN - Target Price and Stock Performance Rundown for Novocure Ltd (NASDAQ:NVCR)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Novocure Ltd (NASDAQ:NVCR) shares ...and more »
05/31/16 05:49 PM3 Biotech Stocks Making Waves - Schaeffers Research (blog) - Schaeffers Research (blog)3 Biotech Stocks Making WavesSchaeffers Research (blog)NVCR received FDA approval to begin a Phase III trial of its radiosurgery cancer treatment. The news had the stock as much as 3.6% higher out of the gate, but the shares have since reversed course, last seen down 0.5% at $11.24. Longer term, Novocure ...and more »
05/31/16 06:42 AMNovocure Receives IDE Approval to Initiate METIS Trial - [at noodls] - Released : 05/31/2016 Phase 3 pivotal trial will study radiosurgery plus Tumor Treating Fields compared to radiosurgery alone for brain metastases from non-small cell lung cancer ST. HELIER, Jersey--(BUSINESS ...
05/29/16 12:00 PMNovocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 6.54% - HNN - Novocure Limited Ord (NASDAQ:NVCR) Shorted Shares Increased By 6.54%HNNThe stock of Novocure Limited Ord (NASDAQ:NVCR) registered an increase of 6.54% in short interest. NVCR's total short interest was 2.45M shares in May as published by FINRA. Its up 6.54% from 2.30M shares, reported previously. With 391,300 shares ...
05/27/16 12:21 PMEarnings Review and Stock Rundown for Novocure Ltd (NASDAQ:NVCR) - Wall Street Hints and News - Earnings Review and Stock Rundown for Novocure Ltd (NASDAQ:NVCR)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Novocure Ltd (NASDAQ:NVCR) to post ...and more »
05/25/16 03:07 PMNOVOCURE LTD Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
05/24/16 10:45 AMEXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel Today - Nasdaq - EXEL Rises On Trial Data, XNPT Agrees To Be Acquired, NVO Faces FDA Panel TodayNasdaqNovocure (NVCR) has enrolled the 40th and the last patient in its phase 2 pilot trial testing Tumor Treating Fields plus chemotherapy, dubbed PANOVA, in advanced pancreatic cancer. The final data collection date will be six months after the last ...and more »
05/23/16 10:58 AMNovocure : Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer - The first cohort testing TTFields plus gemcitabine suggests improved survival and response rate compared to a historical control of gemcitabine alone Novocure (NASDAQ: NVCR) announced today that the last patient has been enrolled in the PANOVA trial ...

Social

About NovoCure

NovoCure logoNovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night. The Company has performed various pre-clinical research on TTFields and their effects in multiple solid tumor cancers.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVCR
  • CUSIP:
Key Metrics:
  • Previous Close: $8.09
  • 50 Day Moving Average: $11.53
  • 200 Day Moving Average: $12.89
  • P/E Ratio: N/A
  • P/E Growth: -1.82
  • Market Cap: $683.76M
  • Current Year EPS Consensus Estimate: $-1.38 EPS
  • Next Year EPS Consensus Estimate: $-0.71 EPS
Additional Links:
NovoCure (NASDAQ:NVCR) Chart for Thursday, July, 28, 2016